Voriconazole into PLGA nanoparticles: Improving agglomeration and antifungal efficacy

Peng, Haisheng; Liu, Xijun; Lv, Gui-xiang; Sun, Bo; Kong, Qingfei; Zhai, Dongxu; Wang, Qi; Wei, Zhao; Wang, Guangyou; Wang, Dandan; Li, Hulun; Jin, Lianhong; Kostulas, Nikolaos

doi:10.1016/j.ijpharm.2007.10.009

Cited by 38 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The higher antibacterial effect of RXN PLGA NPs and PEG-PLGA NPs may have been resulted from higher bacterial adhesion of the NPs. In other studies enhanced antimicrobial activity from PLGA NPs containing antimicrobial agents has been reported [21,22]. The improved the therapeutic effect of the nanoparticulate antibacterial delivery systems may the result of increased drug concentration nearby its target.…”

Section: Resultsmentioning

confidence: 94%

See 1 more Smart Citation

Enhanced antibacterial activity of roxithromycin loaded pegylated poly lactide-co-glycolide nanoparticles

et al. 2012

View full text Add to dashboard Cite

Background and the purpose of the studyThe purpose of this study was to prepare pegylated poly lactide-co-glycolide (PEG-PLGA) nanoparticles (NPs) loaded with roxithromycin (RXN) with appropriate physicochemical properties and antibacterial activity. Roxithromycin, a semi-synthetic derivative of erythromycin, is more stable than erythromycin under acidic conditions and exhibits improved clinical effects.MethodsRXN was loaded in pegylated PLGA NPs in different drug;polymer ratios by solvent evaporation technique and characterized for their size and size distribution, surface charge, surface morphology, drug loading, in vitro drug release profile, and in vitro antibacterial effects on S. aureus, B. subtilis, and S. epidermidis.Results and conclusionNPs were spherical with a relatively mono-dispersed size distribution. The particle size of nanoparticles ranged from 150 to 200 nm. NPs with entrapment efficiency of up to 80.0±6.5% and drug loading of up to 13.0±1.0% were prepared. In vitro release study showed an early burst release of about 50.03±0.99% at 6.5 h and then a slow and steady release of RXN was observed after the burst release. In vitro antibacterial effects determined that the minimal inhibitory concentration (MIC) of RXN loaded PEG-PLGA NPs were 9 times lower on S. aureus, 4.5 times lower on B. subtilis, and 4.5 times lower on S. epidermidis compared to RXN solution. In conclusion it was shown that polymeric NPs enhanced the antibacterial efficacy of RXN substantially.

show abstract

Section: Resultsmentioning

confidence: 94%

“…In this study, PLGA-PEG NPs showed less negative zeta potential (-1.9±0.11) than PLGA NPs (-25.4±0.24). It has been proved that the amount of phagocytosis is the lowest when zeta potential is closer to zero [21]. …”

Section: Resultsmentioning

confidence: 99%

Enhanced antibacterial activity of roxithromycin loaded pegylated poly lactide-co-glycolide nanoparticles

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In a previously conducted study, we have also shown strong antifungal activity with ITZ entrapped PLGANPs at 100-times lower drug concentrations compared with free ITZ [19]. Similarly, Peng et al studied voriconazole-entrapped PLGANPs and showed more potent antifungal efficacy compared with free voriconazole, in vitro and in vivo, [20]. While these studies show a potent antifungal effect by drug entrapment in PLGA-NPs, in general, a mechanism of action is not yet well understood.…”

mentioning

confidence: 69%

Size Dependency of PLGA-Nanoparticle Uptake and Antifungal Activity Against Aspergillus Flavus

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Voriconazole loaded PLGA nanoparticles were developed by Peng et al (2008) in order to improve drug bioavailability and stability for oral delivery (Peng et al, 2008). Nanoparticles had a more persistent and potent antifungal effect than free voriconazole both in vitro and in vivo in a systemic candidiasis murine model.…”

Section: Nanopreparations For Azolesmentioning

confidence: 99%

Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity

Souza

Amaral

2017

Front. Microbiol.

View full text Add to dashboard Cite

Fungal diseases have been emerging as an important public health problem worldwide with the increase in host predisposition factors due to immunological dysregulations, immunosuppressive and/or anticancer therapy. Antifungal therapy for systemic mycosis is limited, most of times expensive and causes important toxic effects. Nanotechnology has become an interesting strategy to improve efficacy of traditional antifungal drugs, which allows lower toxicity, better biodistribution, and drug targeting, with promising results in vitro and in vivo. In this review, we provide a discussion about conventional antifungal and nanoantifungal therapies for systemic mycosis.

show abstract

Voriconazole into PLGA nanoparticles: Improving agglomeration and antifungal efficacy

Cited by 38 publications

References 20 publications

Enhanced antibacterial activity of roxithromycin loaded pegylated poly lactide-co-glycolide nanoparticles

Enhanced antibacterial activity of roxithromycin loaded pegylated poly lactide-co-glycolide nanoparticles

Size Dependency of PLGA-Nanoparticle Uptake and Antifungal Activity Against Aspergillus Flavus

Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity

Contact Info

Product

Resources

About